JOËL JEAN-MAIRET

Joël Jean-Mairet stands as a distinguished General Partner at Ysios Capital, a leading European venture capital firm dedicated to the life sciences sector. His role is pivotal in identifying, evaluating, and supporting groundbreaking companies that are poised to transform healthcare through scientific innovation. Ysios Capital, under his guidance, focuses on early stage and growth stage investments across therapeutics, medical devices, and diagnostics, primarily within Europe.

With an impressive academic and professional background, Joël brings a unique blend of scientific rigor and strategic business acumen to his investments. He holds both an MD and a PhD, providing him with an unparalleled understanding of the complex scientific and clinical challenges faced by biotech companies. Prior to his tenure at Ysios Capital, Joël amassed extensive experience in the pharmaceutical industry, notably at Roche. There, he held various senior leadership positions, including Head of Global Business Development for Pharma, where he was instrumental in shaping strategic partnerships and M&A activities. His career at Roche also encompassed significant roles in research and development, giving him firsthand insight into the drug discovery and development process.

At Ysios Capital, Joël Jean-Mairet leverages this deep expertise to guide portfolio companies from concept to commercialization. His investment focus is broad within life sciences but often gravitates towards novel therapeutics and drug discovery platforms that address significant unmet medical needs. He is particularly adept at recognizing the potential in innovative technologies and scientific breakthroughs that can be translated into viable patient solutions. Joël's involvement extends beyond capital provision; he actively participates on the boards of several portfolio companies, offering strategic guidance on clinical development, regulatory pathways, and market access.

Notable investments and board roles associated with Joël Jean-Mairet include companies like Minoryx Therapeutics, a clinical stage biotech company developing treatments for orphan central nervous system disorders, and Inbrain Neuroelectronics, pioneering graphene-based neural interfaces. He has also been involved with Anaconda Biomed, focused on neurovascular access devices, and previously with STAT-Dx, a molecular diagnostics company acquired by QIAGEN. These examples underscore his commitment to fostering innovation across diverse areas of the life sciences, ultimately aiming to improve patient outcomes and drive significant returns for investors. His leadership at Ysios Capital reinforces the firm's position as a key player in the European biotech investment landscape.